BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 22081002)

  • 21. Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.
    Chen F; Suzuki Y; Nagai N; Sun X; Wang H; Yu J; Marchal G; Ni Y
    Radiology; 2007 Aug; 244(2):429-38. PubMed ID: 17581889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
    Roncal C; Martinez de Lizarrondo S; Salicio A; Chevilley A; Rodriguez JA; Rosell A; Couraud PO; Weksler B; Montaner J; Vivien D; Páramo JA; Orbe J
    Cardiovasc Res; 2017 Aug; 113(10):1219-1229. PubMed ID: 28379489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
    Zhang L; Chopp M; Jia L; Cui Y; Lu M; Zhang ZG
    J Cereb Blood Flow Metab; 2009 Nov; 29(11):1816-24. PubMed ID: 19638998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
    Papadopoulos SM; Chandler WF; Salamat MS; Topol EJ; Sackellares JC
    J Neurosurg; 1987 Sep; 67(3):394-8. PubMed ID: 3112328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model.
    Harada T; Kano T; Katayama Y; Matsuzaki T; Tejima E; Koshinaga M
    Thromb Haemost; 2005 Oct; 94(4):791-6. PubMed ID: 16270632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
    Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
    Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
    Niessen F; Hilger T; Hoehn M; Hossmann KA
    Stroke; 2003 Aug; 34(8):2019-24. PubMed ID: 12843350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
    Lapchak PA; Araujo DM; Song D; Zivin JA
    Stroke; 2002 Jan; 33(1):147-52. PubMed ID: 11779904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
    Zhang Y; Wang Y; Zuo Z; Wang Z; Roy J; Hou Q; Tong E; Hoffmann A; Sperberg E; Bredno J; Berr SS; Xie M; Lee K; Wintermark M
    J Neurol Sci; 2014 Dec; 347(1-2):148-54. PubMed ID: 25292413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.
    Meng W; Wang X; Asahi M; Kano T; Asahi K; Ackerman RH; Lo EH
    J Cereb Blood Flow Metab; 1999 Dec; 19(12):1316-21. PubMed ID: 10598935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
    Esmaeeli-Nadimi A; Kennedy D; Allahtavakoli M
    Eur J Pharmacol; 2015 Oct; 764():55-62. PubMed ID: 26123846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Very Mild Hypothermia (35°C) Postischemia Reduces Infarct Volume and Blood/Brain Barrier Breakdown Following tPA Treatment in the Mouse.
    Cechmanek BK; Tuor UI; Rushforth D; Barber PA
    Ther Hypothermia Temp Manag; 2015 Dec; 5(4):203-8. PubMed ID: 26075540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
    Murakami K; Suzuki M; Suzuki N; Hamajo K; Tsukamoto T; Shimojo M
    Brain Res; 2013 Aug; 1526():84-93. PubMed ID: 23791950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
    Zhang L; Zhang ZG; Ding GL; Jiang Q; Liu X; Meng H; Hozeska A; Zhang C; Li L; Morris D; Zhang RL; Lu M; Chopp M
    Circulation; 2005 Nov; 112(22):3486-94. PubMed ID: 16316970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
    Shehadah A; Chen J; Cui Y; Zhang L; Roberts C; Lu M; Chopp M
    J Neurol Sci; 2011 Oct; 309(1-2):96-101. PubMed ID: 21802695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke.
    Durand A; Chauveau F; Cho TH; Kallus C; Wagner M; Boutitie F; Maucort-Boulch D; Berthezène Y; Wiart M; Nighoghossian N
    Cerebrovasc Dis; 2014; 38(4):268-75. PubMed ID: 25401979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke--an MRI study.
    Kollmar R; Henninger N; Bardutzky J; Schellinger PD; Schäbitz WR; Schwab S
    Exp Neurol; 2004 Nov; 190(1):204-12. PubMed ID: 15473993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W; Hendren J; Qin XJ; Liu KJ
    Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
    Li M; Chen S; Shi X; Lyu C; Zhang Y; Tan M; Wang C; Zang N; Liu X; Hu Y; Shen J; Zhou L; Gu Y
    J Neuroinflammation; 2018 Aug; 15(1):237. PubMed ID: 30139371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.